Working Together Across the Cardiomyopathy Care Pathway
A collaborative working group for organizations committed to improving diagnosis and care in cardiomyopathy.
Join the CollectiveThe Cardiomyopathy Collective is a collaborative working group for organizations working across the cardiomyopathy landscape—biopharma, device, diagnostics, and beyond.
Participation is not contingent on funding or testing. Companies join because they share a common goal: improving diagnosis and care in cardiomyopathy, and learning from one another rather than working in silos.
Separately, some partners may choose to contribute to a pooled sponsored testing effort, which supports shared diagnostic initiatives rather than individual company programs. That participation is optional and does not define membership in the Collective.
"Every company in this space is trying to solve a piece of the same problem. We can either do that work in parallel—or we can do it together."
Despite clear clinical guidelines, the diagnostic gap remains enormous.
Patients wait too long to receive appropriate treatment and care.
Genetic insights that could guide therapy are never obtained.
Without cascade testing, relatives remain undiagnosed.
Real-world data gaps slow research and therapeutic development.
Two distinct pathways, one shared mission.
The agenda is shaped by members. Here are some possibilities:
Shared language and definitions for subtypes, diagnostic criteria, and care pathways.
Understanding how patients move through recognition, testing, and diagnosis—and where gaps exist.
Coordinated efforts to increase appropriate testing and guideline-based care.
Aggregate, de-identified data that benefits the entire field.
We're forming the Cardiomyopathy Collective now and inviting organizations who share our commitment to improving cardiomyopathy care to join us.
Wednesday, March 12, 2025
12:00 PM – 1:00 PM ET
Late March 2025
Informal meetup, details to follow
To RSVP or learn more, contact us:
Contact Us to Join